Evaluation of 28 years of surgical treatment of children and young adults with familial adenomatous polyposis

Booij, Klaske A. C.; Mathus-Vliegen, E. M. H.; Taminiau, J. A. J. M.; Kate, F. J. W. Ten; Slors, J. F. M.; Tabbers, Merit M.; Aronson, Daniël C.

doi:10.1016/j.jpedsurg.2009.06.017

Cited by 18 publications

(13 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…47,48 Although IRA is feasible for patients with attenuated FAP, the increasing risk of CRC in the remaining rectum with age is considerable and has been reported at between 29 and 35% at 25 years after the original procedure. 38,46 In that clinical setting, secondary excision of the rectum may be necessary, as reported by Booij et al, 49 where 7 of 34 patients had completion proctectomy and 2 patients died secondary to invasive rectal cancer. 49 Functionally, there is little choice between IRA and IPAA.…”

Section: Surgical Approachmentioning

confidence: 90%

“…38,46 In that clinical setting, secondary excision of the rectum may be necessary, as reported by Booij et al, 49 where 7 of 34 patients had completion proctectomy and 2 patients died secondary to invasive rectal cancer. 49 Functionally, there is little choice between IRA and IPAA. 50 Newer studies indicate that laparoscopic approaches may have reduced the effect of IPAA on long-term fertility.…”

Section: Surgical Approachmentioning

confidence: 90%

See 1 more Smart Citation

Current Approaches to Pediatric Polyposis Syndromes

Fahy

Moir

2018

Clinics in Colon and Rectal Surgery

View full text Add to dashboard Cite

Colorectal adenomatous polyposis syndromes encompass a diverse group of disorders with varying modes of inheritance and penetrance. Children may present with overt disease or within screening programs for families at high risk. We provide an overview of the array of pediatric polyposis syndromes, current screening recommendations, and surgical indications and technical considerations. Optimal disease management for these pediatric patients is still evolving and has implications for screening, surveillance, pediatric surgical management, and transition of care gastroenterologic neoplasia physicians and surgeons.

show abstract

Section: Surgical Approachmentioning

confidence: 90%

Section: Surgical Approachmentioning

confidence: 90%

Current Approaches to Pediatric Polyposis Syndromes

Fahy

Moir

2018

Clinics in Colon and Rectal Surgery

View full text Add to dashboard Cite

show abstract

“…At present, means to avoid colon cancer development includes removal of the colorectum where malignant epithelial tumors develop [71]. In addition to genetic mutation, lifestyle such as exercise, food, and smoking are involved in the cancerization of FAP [72,73].…”

Section: Apc Min/+ Mouse Colon Carcinogenesis Model By Inflammatory Smentioning

confidence: 99%

Animal Models of Carcinogenesis in Inflamed Colorectum: Potential Use in Chemoprevention Study

Tanaka

2012

CDT

View full text Add to dashboard Cite

Inflammation is a risk factor for cancer development in several tissues. In the colorectum, inflammatory bowel disease (ulcerative colitis and Crohn's disease) is a longstanding inflammatory disease with increased risk for colorectal cancer (CRC). Several molecular events involving in chronic inflammatory process contribute to multi-stage carcinogenesis of CRC in the inflamed colon. They include alterations in production of reactive oxygen and nitrogen species, upregulation of pro-inflammatory cytokines and inflammatory enzymes, and intestinal immune system. In this short review, experimental animal models of inflammation-associated CRC are described. Also, some preclinical data on chemoprevention of inflammation-associated CRC by astaxanthin and a specific inhibitor of nitric oxide synthase using these inflammation-related CRC models is briefly introduced.

show abstract

“…Moreover, surgery does not prevent the development of rectal or ileal pouch polyposis. In one long-term follow-up study, 7/34 (21%) children treated with an IRA required proctectomy for either rectal cancer or advanced rectal polyposis, and 2/7 (29%) FAP patients treated with IPAA had postoperative pouch polyposis within one decade of surgery 7. Another study in patients who had undergone IPAA for FAP 10 years previously found that 42% of patients had developed adenoma of the pouch 8…”

Section: Introductionmentioning

confidence: 99%

Children’s International Polyposis (CHIP) study: a randomized, double-blind, placebo-controlled study of celecoxib in children with familial adenomatous polyposis

Burke¹,

Phillips²,

Berger

et al. 2017

CEG

View full text Add to dashboard Cite

ObjectiveTo evaluate the efficacy and safety of celecoxib versus placebo in the prevention and treatment of colorectal polyposis in children with familial adenomatous polyposis (FAP).MethodsIn this Phase III, double-blind, randomized, placebo-controlled, multicenter trial patients aged 10–17 years with FAP were randomized to celecoxib (16 mg/kg/day) or placebo for up to 5 years. Patients underwent annual assessments, including colonoscopies, to detect the time from randomization to the earliest occurrence of ≥20 polyps (>2 mm in size) or colorectal malignancy. The study was terminated early due to low rate of observed endpoints combined with a lower than expected enrollment rate. Descriptive results are provided.ResultsOf 106 randomized patients, 55 were treated with celecoxib (mean age 12.6 years; 52.7% female) and 51 were given placebo (mean age 12.2 years; 54.9% female). Disease progression (≥20 polyps, >2 mm in size) was observed in seven (12.7%) and 13 (25.5%) patients, respectively. The median time to disease progression was 2.1 years in the celecoxib group and 1.1 years for placebo. No patient developed colorectal cancer. The rate of adverse events (AEs) was similar in both groups (75.5% and 72.9%, respectively). Three patients in the celecoxib group (none in the placebo group) experienced serious AEs.ConclusionIn children with FAP, celecoxib was a well-tolerated treatment that was associated with a lower rate of colorectal polyposis and a longer time to disease progression compared with placebo. Due to the low rate of observed endpoints, the long-term impact of these results could not be ascertained.

show abstract

Evaluation of 28 years of surgical treatment of children and young adults with familial adenomatous polyposis

Cited by 18 publications

References 36 publications

Current Approaches to Pediatric Polyposis Syndromes

Current Approaches to Pediatric Polyposis Syndromes

Animal Models of Carcinogenesis in Inflamed Colorectum: Potential Use in Chemoprevention Study

Children’s International Polyposis (CHIP) study: a randomized, double-blind, placebo-controlled study of celecoxib in children with familial adenomatous polyposis

Contact Info

Product

Resources

About

Evaluation of 28 years of surgical treatment of children and young adults with familial adenomatous polyposis

Cited by 18 publications

References 36 publications

Current Approaches to Pediatric Polyposis Syndromes

Current Approaches to Pediatric Polyposis Syndromes

Animal Models of Carcinogenesis in Inflamed Colorectum: Potential Use in Chemoprevention Study

Children&rsquo;s International Polyposis (CHIP) study: a randomized, double-blind, placebo-controlled study of celecoxib in children with familial adenomatous polyposis

Contact Info

Product

Resources

About

Children’s International Polyposis (CHIP) study: a randomized, double-blind, placebo-controlled study of celecoxib in children with familial adenomatous polyposis